Fig.7.

Effect of VEGF-siRNA and/or doxorubicin treatment on BCL-2 and SURVIVIN protein expression in Hep3B cells. A. Protein expressions of BCL-2 and SURVIVIN in Hep3B cells measured by Western blot analyses after treatment with the indicated concentration of doxorubicin for 48 hours. β-actin was used as a housekeeping gene control. The size of each protein was indicated and B, C. Densitometric analysis of these three proteins relative to β-actin. Each bar represents the mean value ± standard deviation (SD) of triplicate experiments. *; P<0.05, **; P<0.01 compared to control cell group (or medium), #; P<0.05 compared to VEGF-siRNA treated cell group, Dox 0; 0 μg/ml (or medium) doxorubicin, Dox 1; 1 μg/ml doxorubicin, Dox 2; 2 μg/ml doxorubicin, Dox 4: 4 μg/ml doxorubicin and VEGF-siRNA; Vascular endothelial growth factor targeted small-interfering RNA.